Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–28 of 4 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: 13-valent Pneumococcal Vaccine Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

NCT03621670
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
56
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jul 23, 2026, 5:20 AM EDT
Active, not recruiting Not applicable Interventional

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

NCT01527591
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Pneumococcal Conjugate Vaccine 13 (PCV13)
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Months to 59 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jul 23, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 23, 2026, 5:20 AM EDT